Core Viewpoint - The company completed a Series A financing round of 80 million RMB, aimed at advancing its clinical trials and drug development in targeted therapies for malignant metastatic solid tumors [1] Group 1: Financing Details - The financing round was led by multiple investors including Jingtai Technology, Songhe Capital, Zhisheng Collaborative, Tiantu Yayi Capital, and Blue Ocean Capital [1] - The funds will primarily support the global Phase II clinical trial of the company's first pipeline, SIGX1094, and the IND application and Phase I clinical trial of the second pipeline, SIGX2649 [1] Group 2: Business Expansion - In addition to the clinical pipelines, the financing will also enhance the company's organoid platform to empower drug innovation and research [1]